Search

Displaying results 5951 - 5960 of 7687 in total
  1. Drug

    Flezurafenib

    go.drugbank.com/drugs/DB21725
    Experimental

    Flezurafenib has a monoisotopic molecular weight of 456.16 Da.

  2. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

  3. Drug

    Gambir

    go.drugbank.com/drugs/DB14298
    Investigational

    It is not an approved drug.

  4. Drug

    Pomegranate

    go.drugbank.com/drugs/DB14317
    Investigational

    It is not an approved drug.

  5. Drug

    IBIO-100

    go.drugbank.com/drugs/DB18233
    Experimental

    IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.

  6. Drug

    VOR33

    go.drugbank.com/drugs/DB18624
    Investigational

    VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.

  7. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  8. Drug

    Gadopentetic acid

    go.drugbank.com/drugs/DB00789
    ApprovedInvestigational

    A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)

  9. Drug

    Diethylamino hydroxybenzoyl hexyl benzoate

    go.drugbank.com/drugs/DB11269
    Approved

    Minimizing the overexposure of human skin to ultraviolet radiation that may lead to acute and chronic photodamage, diethylamino hydroxybenzoyl hexyl benzoate is an oil-soluble UV filter that may be incorporated

    Mixtures: D-one By Tamdoan Bb Light, D-one By Tamdoan Bb Medium
  10. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). … addition, however, preclinical data demonstrates that OXI-4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor infiltrates, to an